Press release,
The aim of the partnership is to enable personalised treatments for difficult neurological disorders more effectively than at present, and to make them better available in the Finnish private sector.
“Mental health disorders are becoming public health issues1, and medical treatment is not suitable for all patients. Our neuronavigated TMS technology enables accurate mapping and treatment of the brain for patients with major neurological diseases and disorders. This cooperation with Recuror is our response to medical needs for an even more effective and quicker rehabilitation.
One of our strategic goals for 2021 is to develop and engage in partnerships in the therapy markets, and this cooperation with Recuror is a good example of the implementation of our strategy.
We are highly excited about this cooperation with Recuror’s professionals and about being able to make treatments supported by targeted magnetic stimulation more broadly available in Finland.”
“Each patient deserves access to rapid help through the most recent and effective treatments in psychiatry, including magnetic stimulation. Recuror offers a direct route to magnetic stimulation, which would only be available after years of waiting in the public sector. Magnetic stimulation is part of Recuror’s comprehensive, multidisciplinary and targeted treatments, supporting recovery in the best way possible. Our experienced medical specialists have expertise in the concrete impact of magnetic stimulation on the treatment of psychological issues and pain syndromes.”
1: Markkula, N., Suvisaari, J., Saarni, S. I., Pirkola, S., Peña, S., Saarni, S., Ahola, K., Mattila, A. K., Viertiö, S., Strehle, J., Koskinen, S., & Härkänen, T. (2015). Prevalence and correlates of major depressive disorder and dysthymia in an eleven-year follow-up – results from the
Further information is available on the website www.nexstim.com, or by contacting:
+358 50 326 4101
mikko.karvinen@nexstim.com
+358 30 6217341
mika.kallio@recuror.fi
About
Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in
For more information, please visit www.nexstim.com
Recuror in brief
Recuror Oy offers a direct route to the best treatment of psychological issues and chronic pain syndromes, which would only be available after years of waiting in the public sector. The comprehensive treatment of patients is guaranteed by a multidisciplinary team of medical specialists. As the only private psychiatry centre in
Attachment
- Nexstim Plc_Press release_Private clinic_05112021_FINAL_EN
© OMX, source